NCT07624305ClinicalTrials.gov
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)
In breve
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…
Fase 32800 partecipanti ricercati478 centri27 paesi
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT07624305Apri questa scheda su ClinicalTrials.govSincronizzato 2 mesi fa
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.
How this score is built
- Enrolment34/40
2,800 participants (target)
- Site count19/25
45 sites
- Country count12/15
8 countries
- Planned duration9/10
Planned over about 47 months
- Sponsor scale10/10
AstraZeneca has led 999 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.
Patologie
- Renal Insufficiency, Chronic
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – 99 Years |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Fase 3 |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | TREATMENT |
| Mascheramento | QUADRUPLE (4) |
| Arruolamento | 2800 partecipanti ricercati |
Sponsor e collaboratori
- AstraZeneca Sponsor
Bracci e interventi
- Balcinrenone/dapagliflozinEXPERIMENTAL
Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.
- DapagliflozinACTIVE_COMPARATOR
Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.
Interventi
- Farmaco Balcinrenone/dapagliflozin
balcinrenone/dapagliflozin 15 mg/10 mg
- Farmaco Dapagliflozin
dapagliflozin 10 mg
- Farmaco Placebo matching Dapagliflozin
matching placebo for dapagliflozin 10 mg
- Farmaco Placebo matching balcinrenone/dapagliflozin
matching placebo for balcinrenone/dapagliflozin
Esiti misurati
Esito primario
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation
Orizzonte temporale Up to 46 months.
Esito secondario
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR
Orizzonte temporale Up to 46 months.
Esito secondario
Change in urinary albumin to creatinine ratio to Week 24
Change from baseline to Week 24 in urinary albumin to creatinine ratio
Orizzonte temporale Baseline to Week 24
Esito secondario
Time to first occurrence of cardiovascular death or heart failure event.
Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation
Orizzonte temporale Up to 46 months.
Esito secondario
Time to cardiovascular death
Time from randomization to cardiovascular death.
Orizzonte temporale Up to 46 months.
Esito secondario
Time to death from any cause
Time from randomization to death from any cause.
Orizzonte temporale Up to 46 months.
Date
| Data di inizio | 1 settembre 2026 (effettiva) |
|---|---|
| Conclusione primaria | 1 luglio 2030 (stimata) |
| Conclusione | 1 luglio 2030 (stimata) |
| Prima pubblicazione | 3 giugno 2026 (effettiva) |
| Ultimo aggiornamento | 24 settembre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | settembre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
33 centri stanno reclutando
Argentina
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | CABA | Non ancora in reclutamento | |
| Research Site | Capital Federal | Non ancora in reclutamento | |
| Research Site | Ciudad de Buenos Aires | Non ancora in reclutamento | |
| Research Site | La Plata | Non ancora in reclutamento | |
| Research Site | Lanús Este | Non ancora in reclutamento | |
| Research Site | Mar del Plata | Non ancora in reclutamento | |
| Research Site | Rosario | Non ancora in reclutamento | |
| Research Site | Rosario | Non ancora in reclutamento | |
| Research Site | Rosario | Non ancora in reclutamento | |
| Research Site | San Nicolás | Non ancora in reclutamento | |
| Research Site | Santa Fe | Non ancora in reclutamento | |
| Research Site | Santa Fe | Non ancora in reclutamento |
Austria
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Feldkirch | Non ancora in reclutamento | |
| Research Site | Innsbruck | Non ancora in reclutamento | |
| Research Site | Linz | Non ancora in reclutamento | |
| Research Site | Sankt Pölten | Non ancora in reclutamento | |
| Research Site | Vienna | Non ancora in reclutamento | |
| Research Site | Vienna | Non ancora in reclutamento | |
| Research Site | Vienna | Non ancora in reclutamento | |
| Research Site | Vienna | Non ancora in reclutamento | |
| Research Site | Wels | Non ancora in reclutamento | |
| Research Site | Wiener Neustadt | Non ancora in reclutamento |
Brazil
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Barretos | Non ancora in reclutamento | |
| Research Site | Belo Horizonte | Non ancora in reclutamento | |
| Research Site | Belo Horizonte | Non ancora in reclutamento | |
| Research Site | Belém | Non ancora in reclutamento | |
| Research Site | Campinas | Non ancora in reclutamento | |
| Research Site | Goiânia | Non ancora in reclutamento | |
| Research Site | Natal | Non ancora in reclutamento | |
| Research Site | Recife | Non ancora in reclutamento | |
| Research Site | São Caetano do Sul | Non ancora in reclutamento | |
| Research Site | São José do Rio Preto | Non ancora in reclutamento | |
| Research Site | São José dos Campos | Non ancora in reclutamento | |
| Research Site | São Paulo | Non ancora in reclutamento | |
| Research Site | São Paulo | Non ancora in reclutamento | |
| Research Site | São Paulo | Non ancora in reclutamento | |
| Research Site | São Paulo | Non ancora in reclutamento |
Bulgaria
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Blagoevgrad | Non ancora in reclutamento | |
| Research Site | Nova Zagora | Non ancora in reclutamento | |
| Research Site | Pleven | Non ancora in reclutamento | |
| Research Site | Plovdiv | Non ancora in reclutamento | |
| Research Site | Sandanski | Non ancora in reclutamento | |
| Research Site | Sevlievo | Non ancora in reclutamento | |
| Research Site | Sofia | Non ancora in reclutamento | |
| Research Site | Sofia | Non ancora in reclutamento | |
| Research Site | Sofia | Non ancora in reclutamento | |
| Research Site | Stara Zagora | Non ancora in reclutamento | |
| Research Site | Varna | Non ancora in reclutamento |
Canada
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Research Site | Brampton | Ontario | Non ancora in reclutamento |
| Research Site | Calgary | Alberta | Ritirato |
Nella scheda del registro sono indicati altri 428 centri.
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 24 settembre 2026
Stato modificato
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 24 settembre 2026
Reclutamento aperto
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 24 settembre 2026
Centro aggiunto
433 sites added (478 total)
45478